Title

Effectiveness of Contrast-Enhanced Ultrasound
Clinical Effectiveness of Contrast-Enhanced Ultrasound in the Evaluation of Blunt Abdominal Trauma in Young Children
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Active, not recruiting
  • Study Participants

    120
The purpose of the study is to generate pilot data describing test characteristics of contrast enhanced ultrasound in young children with concern for abdominal trauma. The primary objective in this study is to determine the sensitivity and specificity of contrast-enhanced ultrasound (CEUS) compared to abdominal Computed Tomography (CT) in the detection of abdominal solid organ injury in young children < 8 years of age with concern for blunt abdominal trauma.
Abdominal trauma in children can be deadly, but intra-abdominal injuries can be difficult to detect and often lack external signs of injury on physical exam. The current gold standard imaging study is Computed Tomography (CT) with IV contrast, which is associated with radiation exposure. Contrast-enhanced ultrasound is a radiation-free alternative to detect abdominal injuries and has been studied primarily in adults and some older children, but evidence to support its use in young children is needed.

This is a prospective study of children less than 8 years of age who are clinically stable and undergoing an abdominal CT with IV contrast as part of their clinical care due to concerns for abdominal trauma. Investigators will compare CEUS results with those obtained by CT. Investigators will additionally include retrospective data of children who underwent both abdominal CT and CEUS as part of clinical care.
Study Started
May 09
2018
Primary Completion
Dec 31
2024
Anticipated
Study Completion
Dec 31
2024
Anticipated
Last Update
Dec 28
2023
Estimate

Drug Contrast-Enhanced Ultrasound using Lumason

Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound

  • Other names: SonoVue (25 mg under sulfur hexafluoride gas) / Lumason, Sulfur hexafluoride microbubbles for injection, US Patent No. 5,686,060

Retrospective Review No Intervention

Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).

Prospective Observation No Intervention

Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.

Contrast-Enhanced Ultrasound using Lumason Other

Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.

Criteria

Inclusion Criteria for study CEUS

Males or females < 8 years of age at time of enrollment
Clinically stable (defined as not undergoing an emergent surgical procedure in the next hour)
Abdominal CT ordered or obtained
IV in place

Exclusion Criteria for study CEUS

Unable to obtain contrast-enhanced ultrasound within 72 hours after CT
History of allergic reaction to Lumason, sulfa-hexafluoride lipid microsphere components, or other ingredients in Lumason (polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na) palmitic acid)
Known congenital or acquired heart disease

Alternative Inclusion and Exclusion Criteria for children who have undergone or are undergoing CEUS as part of clinical care

Inclusion criteria:

Males or females < 8 years of age at time of CEUS.
Clinical Team plans to perform CT or has performed CT as part of clinical care for abdominal trauma
Clinical Team plans to perform (or has performed) CEUS as part of clinical care
Date of CEUS after January 1, 2015

Exclusion Criteria: None
No Results Posted